Merck KGaA (MKKGY) – What Are Investment Firms Thinking About This Stock?

Merck KGaA (OTCMKTS:MKKGY) has earned a consensus rating of “Reduce” from the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company.

Several research firms have commented on MKKGY. UBS Group cut shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Zacks Research lowered Merck KGaA from a “hold” rating to a “strong sell” rating in a research note on Monday, October 12th.

Merck KGaA Stock Performance

OTCMKTS:MKKGY opened at $33.73 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The firm has a market cap of $21.80 billion, a PE ratio of 17.39, a P/E/G ratio of 2.93 and a beta of 0.92. The firm has a 50 day simple moving average of $31.68 and a 200-day simple moving average of $30.05. Merck KGaA has a 1-year low of $23.73 and a 1-year high of $34.19.

Merck KGaA Company Profile

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.